Drug Trial Radar · NCT00841126
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate
Last checked: Nov 20, 2026Latest source record: Oct 19, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
657
Planned (sponsor's estimate)
Start
Jul 2009
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- Ineos Healthcare LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring hemodialysis, compared with a marketed phosphate binder, lanthanum carbonate and placebo.
Conditions
- Chronic Kidney Failure
Interventions
Magnesium iron hydroxycarbonateDrug
500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
Lanthanum carbonateDrug
750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
PlaceboDrug
0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Control or not the level of serum phosphateTime frame: Within the treatment period
- Stage 2: Change from treated baseline in mean serum phosphateTime frame: At 4 weeks
Locations
112 sites in 11 countries. Site status is shown where the registry gives one.
Nephrology Associates PC
Birmingham, Alabama
Arizona Kidney Disease and Hypertension Center
Phoenix, Arizona
Southwest Kidney Institute
Tempe, Arizona
US Renal Care
Jonesboro, Arkansas
Wright Steven (Private Practice)
Pine Bluff, Arkansas
University of Southern California
Los Angeles, California
Apex Research of Riverside
Riverside, California
North America Research Institute
San Dimas, California
Kidney Center Inc.
Simi Valley, California
Nephrology Educational Services and Research
Tarzana, California
American Institute of Research
Whittier, California
North Valley Nephrology
Yoba City, California
Western Nephrology & Metabolic Bone Disease PC
Arvada, Colorado
Western Nephrology & Metabolic Bone Disease PC
Westminister, Colorado
Nephrology and Hypertension Associates
Middlebury, Connecticut
South Florida Nephrology Group P.A.
Coral Springs, Florida
Outcomes Research International Inc.
Hudson, Florida
Nephrology Associates of South Miami
Miami, Florida
Nephrology Associates Research Center
Panama City, Florida
Cleveland Clinic Florida
Weston, Florida
Renal Physicians of Georgia PC
Macon, Georgia
Boise Kidney & Hypertension Institute
Meridian, Idaho
Research by Design LLC
Evergreen Park, Illinois
North Suburban Nephrology
Gurnee, Illinois
Kansas Nephrology Research Institute LLC
Wichita, Kansas
Research Nurse Specialists LLC
Lafayette, Louisiana
Lazowski Piotr MD- PC
Plymouth, Massachusetts
Fallon Clinic - Winthrop
Worcester, Massachusetts
William Beaumont Hospitals
Berkley, Michigan
St. Clair Specialty Physicians PC
Detroit, Michigan
Nephrology Associates P.C.
Columbus, Mississippi
Creighton University
Omaha, Nebraska
Kantor Nephrology Consultants Ltd.
Las Vagas, Nevada
Brookdale Physicians Dialysis Associates
Brooklyn, New York
Hypertension and Renal Research Group
Buffalo, New York
Lower Manhattan Dialysis Center
New York, New York
Long Island Hypertension and Nephrology PLLC
Port Washington, New York
Wake Nephrology Associates PA
Raleigh, North Carolina
University of Cincinnati Medical Center
Cinncinnati, Ohio
MetroHealth Medical Center
Cleveland, Ohio
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.